Mind Medicine (MindMed) Stock (NASDAQ:MNMD)

Forecast Revenue Ownership Financials Chart Transcripts

Previous Close

$7.43

52W Range

$3.82 - $12.22

50D Avg

$7.32

200D Avg

$7.36

Market Cap

$536.79M

Avg Vol (3M)

$1.49M

Beta

2.33

Div Yield

MNMD Company Profile

Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders related to psychiatry, addiction, pain, and neurology. The company develops MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder, as well as for the treatment of chronic pain; and MM-110, an a3ß4 nicotinic cholinergic receptor antagonist that has completed phase 1 for the treatment of opioid withdrawal. It also develops MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine for the treatment of core symptoms of autism spectrum disorder. The company is headquartered in Vancouver, Canada.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

Country

Employees

IPO Date

Nov 15, 2016

Website

MNMD Performance

MNMD Financial Summary

	Dec 23	Dec 22	Dec 21
Revenue	-	-	-
Operating Income	$-93.87M	$-66.33M	$-96.36M
Net Income	$-95.73M	$-47.26M	$-93.04M
EBITDA	$-93.87M	$-74.37M	$-93.75M
Basic EPS	-	$-1.53	$-3.40
Diluted EPS	-	$-1.53	$-3.40

Fiscal year ends in Dec 23 | Currency in USD

Latest Earnings Call Transcripts

Q1 24May 08, 24 | 4:30 PM

Q3 23Nov 02, 23 | 4:30 PM

Q2 23Aug 03, 23 | 4:30 PM

Peer Comparison

Ticker	Company
MOLN	Molecular Partners AG
CKPT	Checkpoint Therapeutics, Inc.
ATAI	Atai Life Sciences N.V.
OPT	Opthea Limited
GHRS	GH Research PLC
KOD	Kodiak Sciences Inc.
ITOS	iTeos Therapeutics, Inc.
EWTX	Edgewise Therapeutics, Inc.
RVPH	Reviva Pharmaceuticals Holdings, Inc.
BPTH	Bio-Path Holdings, Inc.
MBIO	Mustang Bio, Inc.